Skip to main content
NASDAQ:RAPT

RAPT Therapeutics Competitors

$19.12
+0.62 (+3.35 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.44
$20.04
50-Day Range
$18.50
$23.56
52-Week Range
$14.09
$41.86
Volume109,838 shs
Average Volume144,908 shs
Market Capitalization$475.48 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.03

Competitors

RAPT Therapeutics (NASDAQ:RAPT) Vs. MYOV, IRWD, MORF, FPRX, CYTK, and MGNX

Should you be buying RAPT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to RAPT Therapeutics, including Myovant Sciences (MYOV), Ironwood Pharmaceuticals (IRWD), Morphic (MORF), Five Prime Therapeutics (FPRX), Cytokinetics (CYTK), and MacroGenics (MGNX).

Myovant Sciences (NYSE:MYOV) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Myovant Sciences and RAPT Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Myovant Sciences03302.50
RAPT Therapeutics00403.00

Myovant Sciences presently has a consensus price target of $32.1667, suggesting a potential upside of 55.62%. RAPT Therapeutics has a consensus price target of $42.00, suggesting a potential upside of 119.67%. Given RAPT Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe RAPT Therapeutics is more favorable than Myovant Sciences.

Risk & Volatility

Myovant Sciences has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Insider and Institutional Ownership

33.8% of Myovant Sciences shares are owned by institutional investors. Comparatively, 65.0% of RAPT Therapeutics shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 31.0% of RAPT Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Myovant Sciences and RAPT Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Myovant SciencesN/AN/A-201.20%
RAPT TherapeuticsN/A-48.78%-42.35%

Earnings and Valuation

This table compares Myovant Sciences and RAPT Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myovant SciencesN/AN/A$-288,990,000.00($3.37)-6.13
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.93

Myovant Sciences is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

RAPT Therapeutics beats Myovant Sciences on 7 of the 11 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are owned by institutional investors. 31.0% of RAPT Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares RAPT Therapeutics and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RAPT TherapeuticsN/A-48.78%-42.35%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Valuation and Earnings

This table compares RAPT Therapeutics and Ironwood Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.93
Ironwood Pharmaceuticals$428.41 million4.19$21.50 million$0.5520.29

Ironwood Pharmaceuticals has higher revenue and earnings than RAPT Therapeutics. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for RAPT Therapeutics and Ironwood Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RAPT Therapeutics00403.00
Ironwood Pharmaceuticals03102.25

RAPT Therapeutics currently has a consensus price target of $42.00, indicating a potential upside of 119.67%. Ironwood Pharmaceuticals has a consensus price target of $11.50, indicating a potential upside of 3.05%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe RAPT Therapeutics is more favorable than Ironwood Pharmaceuticals.

Summary

Ironwood Pharmaceuticals beats RAPT Therapeutics on 7 of the 13 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for RAPT Therapeutics and Morphic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RAPT Therapeutics00403.00
Morphic00203.00

RAPT Therapeutics presently has a consensus target price of $42.00, indicating a potential upside of 119.67%. Morphic has a consensus target price of $85.00, indicating a potential upside of 72.59%. Given RAPT Therapeutics' higher probable upside, research analysts plainly believe RAPT Therapeutics is more favorable than Morphic.

Risk & Volatility

RAPT Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Insider and Institutional Ownership

65.0% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 31.0% of RAPT Therapeutics shares are held by insiders. Comparatively, 39.5% of Morphic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares RAPT Therapeutics and Morphic's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.93
Morphic$16.98 million105.04$-43,330,000.00($2.69)-18.31

RAPT Therapeutics has higher earnings, but lower revenue than Morphic. Morphic is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RAPT Therapeutics and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RAPT TherapeuticsN/A-48.78%-42.35%
MorphicN/A-36.62%-20.69%

Summary

Morphic beats RAPT Therapeutics on 6 of the 11 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Valuation & Earnings

This table compares RAPT Therapeutics and Five Prime Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.93
Five Prime Therapeutics$14.87 million119.01$-137,200,000.00($3.92)-9.69

RAPT Therapeutics has higher earnings, but lower revenue than Five Prime Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares RAPT Therapeutics and Five Prime Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RAPT TherapeuticsN/A-48.78%-42.35%
Five Prime Therapeutics-554.71%-75.84%-49.08%

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 31.0% of RAPT Therapeutics shares are held by insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for RAPT Therapeutics and Five Prime Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RAPT Therapeutics00403.00
Five Prime Therapeutics06202.25

RAPT Therapeutics presently has a consensus price target of $42.00, indicating a potential upside of 119.67%. Five Prime Therapeutics has a consensus price target of $30.7143, indicating a potential downside of 19.17%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe RAPT Therapeutics is more favorable than Five Prime Therapeutics.

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, suggesting that its share price is 340% more volatile than the S&P 500.

Summary

RAPT Therapeutics beats Five Prime Therapeutics on 9 of the 13 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares RAPT Therapeutics and Cytokinetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RAPT TherapeuticsN/A-48.78%-42.35%
Cytokinetics-209.88%-3,065.14%-36.39%

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for RAPT Therapeutics and Cytokinetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RAPT Therapeutics00403.00
Cytokinetics011002.91

RAPT Therapeutics presently has a consensus price target of $42.00, indicating a potential upside of 119.67%. Cytokinetics has a consensus price target of $35.5455, indicating a potential upside of 46.16%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe RAPT Therapeutics is more favorable than Cytokinetics.

Valuation & Earnings

This table compares RAPT Therapeutics and Cytokinetics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.93
Cytokinetics$26.87 million64.93$-121,690,000.00($2.11)-11.53

RAPT Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 31.0% of RAPT Therapeutics shares are held by insiders. Comparatively, 6.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

RAPT Therapeutics beats Cytokinetics on 7 of the 13 factors compared between the two stocks.

RAPT Therapeutics (NASDAQ:RAPT) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for RAPT Therapeutics and MacroGenics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RAPT Therapeutics00403.00
MacroGenics11802.70

RAPT Therapeutics currently has a consensus target price of $42.00, indicating a potential upside of 119.67%. MacroGenics has a consensus target price of $34.7778, indicating a potential upside of 20.17%. Given RAPT Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe RAPT Therapeutics is more favorable than MacroGenics.

Insider & Institutional Ownership

65.0% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of MacroGenics shares are owned by institutional investors. 31.0% of RAPT Therapeutics shares are owned by company insiders. Comparatively, 9.0% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares RAPT Therapeutics and MacroGenics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RAPT TherapeuticsN/A-48.78%-42.35%
MacroGenics-204.31%-65.84%-49.41%

Volatility & Risk

RAPT Therapeutics has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.

Earnings and Valuation

This table compares RAPT Therapeutics and MacroGenics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.93
MacroGenics$64.19 million27.07$-151,810,000.00($3.16)-9.16

RAPT Therapeutics has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

RAPT Therapeutics beats MacroGenics on 8 of the 13 factors compared between the two stocks.


RAPT Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$20.67+4.4%$1.88 billionN/A-7.36Earnings Announcement
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.16+1.5%$1.80 billion$428.41 million16.17Earnings Announcement
Morphic logo
MORF
Morphic
1.5$49.25+2.7%$1.78 billion$16.98 million-31.57Analyst Report
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00+0.0%$1.77 billion$14.87 million-14.18
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.32+2.3%$1.74 billion$26.87 million-12.73Earnings Announcement
Analyst Report
MacroGenics logo
MGNX
MacroGenics
1.4$28.94+5.6%$1.74 billion$64.19 million-9.25
Generation Bio logo
GBIO
Generation Bio
1.8$30.60+0.8%$1.73 billionN/A0.00Earnings Announcement
News Coverage
Amarin logo
AMRN
Amarin
1.6$4.35+6.0%$1.71 billion$429.76 million-86.98Analyst Downgrade
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$24.75+1.5%$1.64 billionN/A-15.18Earnings Announcement
Analyst Downgrade
Analyst Revision
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$19.74+4.8%$1.63 billionN/A0.00
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.41+6.1%$1.60 billion$145.97 million-7.05Earnings Announcement
Analyst Upgrade
Analyst Revision
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.32+2.3%$1.60 billion$1.63 billion12.98Earnings Announcement
Analyst Upgrade
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$44.30+7.0%$1.57 billionN/A0.00Earnings Announcement
Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.43+0.2%$1.56 billion$392.76 million12.21Analyst Revision
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.13+4.3%$1.54 billionN/A0.00Earnings Announcement
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$37.49+4.6%$1.50 billionN/A-156.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$21.69+0.4%$1.49 billion$2.34 million-9.19Analyst Report
Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$42.07+6.9%$1.48 billionN/A0.00Gap Down
uniQure logo
QURE
uniQure
1.7$31.97+2.6%$1.47 billion$7.28 million-8.48Earnings Announcement
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$11.29+0.5%$1.45 billion$320,000.00-7.68
Kronos Bio logo
KRON
Kronos Bio
1.7$25.43+3.7%$1.43 billionN/A0.00Earnings Announcement
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.00+1.7%$1.40 billionN/A0.00Analyst Report
Gap Up
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.26+8.7%$1.37 billionN/A-2.95
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$31.30+4.1%$1.36 billionN/A-10.54Earnings Announcement
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.5$35.81+0.9%$1.31 billionN/A-19.89Earnings Announcement
Analyst Upgrade
Analyst Revision
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.56+4.7%$1.31 billion$82.27 million-16.00Earnings Announcement
Analyst Report
Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$29.29+0.8%$1.29 billion$230,000.00-13.62Analyst Revision
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$29.60+2.1%$1.29 billion$6.20 million-12.98News Coverage
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$27.58+2.9%$1.27 billion$29.54 million-7.32Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.6$28.33+1.1%$1.27 billionN/A0.00Insider Selling
High Trading Volume
News Coverage
Endo International logo
ENDP
Endo International
1.5$5.43+5.0%$1.27 billion$2.91 billion-7.99Earnings Announcement
Analyst Revision
Innoviva logo
INVA
Innoviva
1.1$12.37+1.9%$1.25 billion$261.02 million6.31
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.87+1.7%$1.23 billion$73.41 million-3.99Analyst Report
Analyst Revision
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.59+2.3%$1.19 billion$59.70 million-195.90
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$32.21+2.2%$1.19 billionN/A0.00
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.38+2.4%$1.17 billion$4.23 million-8.59Analyst Revision
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$19.39+2.3%$1.17 billion$175.34 million-11.41Earnings Announcement
Shattuck Labs logo
STTK
Shattuck Labs
1.5$27.75+2.7%$1.16 billionN/A0.00Earnings Announcement
Insider Selling
High Trading Volume
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$21.77+2.8%$1.13 billion$4.23 million-16.13Earnings Announcement
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$48.54+4.3%$1.13 billionN/A0.00Earnings Announcement
Analyst Downgrade
Analyst Revision
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$31.15+5.5%$1.12 billion$57.05 million0.00Earnings Announcement
Gap Down
Omeros logo
OMER
Omeros
1.4$17.85+3.2%$1.11 billion$111.81 million-7.50Earnings Announcement
Analyst Downgrade
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$35.08+2.8%$1.10 billionN/A-2.51Analyst Upgrade
Gap Up
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.13+2.2%$1.06 billionN/A-6.95
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.6$26.04+1.3%$1.05 billion$800.40 million24.57Earnings Announcement
Zogenix logo
ZGNX
Zogenix
2.0$18.59+0.8%$1.04 billion$3.65 million-1.95Earnings Announcement
Insider Buying
Analyst Revision
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$49.91+1.5%$1.01 billion$122.47 million-27.42Earnings Announcement
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$14.73+3.9%$1.01 billionN/A-6.22
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$14.51+0.7%$1.00 billion$42.12 million-10.75Earnings Announcement
MannKind logo
MNKD
MannKind
1.4$4.02+9.5%$1.00 billion$63.04 million-19.14Earnings Announcement
Gap Down
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.